Basic Search  |  Summaries  |  Advanced Search

Violation Tracker Individual Record

Company: Endo Pharmaceuticals Inc.
Current Parent Company: Endo International
Penalty: $40,000,000
Year: 2018
Date: September 12, 2018
Offense Group: competition-related offenses
Primary Offense: price-fixing or anti-competitive practices
Secondary Offense: generic drug pay for delay
Mega-Scandal: Generic Drug Pay for Delay
Violation Description: Endo agreed to pay $40 million to end-payor plaintiffs to settle its role in litigation alleging it was part of a conspiracy to delay the release of a generic version of the Lidoderm pain patch.
Level of Government: federal
Action Type: private litigation
Court: Northern District of California
Civil or Criminal Case: civil
Case ID: 3:14md2521
Case Name: In re Lidoderm Antitrust Litigation
Private Lawsuit Resolution Type: settlement
HQ Country of Current Parent: Ireland
Ownership Structure of Current Parent: publicly traded
Major Industry of Current Parent: pharmaceuticals
Specific Industry of Current Parent: pharmaceuticals
Source of Data: (click here)
Link to PACER Case Docket (must be logged in): (click here)
Link to Archived Court Document:  subscribe to see this data field
Source Notes: If an online information source is not working, check the Violation Tracker Data Sources page for an updated link.
Current parent company note: Parent-subsidiary relationship is current as of the most recent revision listed in the Update Log.